Neutraceutical-Based Topical Anxiolytic Agent and Method of Use
A nutraceutical-based anxiolytic agent (composition) for topical application is described. The formulation utilizes a combination of active ingredients directed to up-regulate the parasympathetic nervous system and calming vagal nerve enervation and its resultant stress symptomatology. The active ingredients in the topical composition include GABA (gamma-aminobutyric acid), L-theanine, Phenibut (beta-phenyl-gamma-aminobutyric acid), and casein tryptic hydrolysase. The active ingredients are dissolved in a lecithin organogel carrier such as Lipoderm or Phloderm to provide a superior transdermal delivery system.
1 . An anxiolytic, transdermal, topical composition for the amelioration and management of the physiological symptoms of anxiety, wherein the composition is a mixture comprising:
(a) a pharmacologically active quantity of GABA;
(b) a pharmacologically active quantity of L-Theanine;
(c) a pharmacologically active quantity of Phenibut;
(d) a pharmacologically active quantity of Casein tryptic hydrolysase; and
(e) a topical transdermal carrier.
2 . A method for the amelioration and management of the physiological symptoms of anxiety, the method comprising topically administering a quantity of a composition comprising a mixture of:
(a) a pharmacologically active quantity of GABA;
(b) a pharmacologically active quantity of L-Theanine;
(c) a pharmacologically active quantity of Phenibut;
(d) a pharmacologically active quantity of Casein tryptic hydrolysase; and
(e) a topical transdermal carrier.